US FDA’s Drug Shortage Program On ‘Site Engagement’ To Be Nixed In GDUFA III

 
• By Derrick Gingery
  
Pharmaceutical manufacturing line
Facility inspections remained a discussion topic during GDUFA III negotiations in April. • Source: Alamy

More from Generics

More from Biosimilars & Generics